MRKMerck Sharp & Dohme LLCSigning up patients
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,200 (planned)
- Started
- Dec 13, 2023
- Main results expected
- Sep 7, 2032
- Fully finished
- Sep 7, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) per Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 44 months
Progression-Free Survival (PFS) per iwCLL Criteria 2018 as assessed by BICR
Measured over: Up to approximately 104 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06136559 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC